123 related articles for article (PubMed ID: 24806546)
1. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
[TBL] [Abstract][Full Text] [Related]
2. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
[TBL] [Abstract][Full Text] [Related]
3. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
[TBL] [Abstract][Full Text] [Related]
4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
5. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.
Traxlmayr MW; Lobner E; Antes B; Kainer M; Wiederkum S; Hasenhindl C; Stadlmayr G; Rüker F; Woisetschläger M; Moulder K; Obinger C
Protein Eng Des Sel; 2013 Apr; 26(4):255-65. PubMed ID: 23267121
[TBL] [Abstract][Full Text] [Related]
6. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies.
Lobner E; Humm AS; Göritzer K; Mlynek G; Puchinger MG; Hasenhindl C; Rüker F; Traxlmayr MW; Djinović-Carugo K; Obinger C
Structure; 2017 Jun; 25(6):878-889.e5. PubMed ID: 28528777
[TBL] [Abstract][Full Text] [Related]
7. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
[TBL] [Abstract][Full Text] [Related]
8. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.
Leung KM; Batey S; Rowlands R; Isaac SJ; Jones P; Drewett V; Carvalho J; Gaspar M; Weller S; Medcalf M; Wydro MM; Pegram R; Mudde GC; Bauer A; Moulder K; Woisetschläger M; Tuna M; Haurum JS; Sun H
Mol Ther; 2015 Nov; 23(11):1722-1733. PubMed ID: 26234505
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
11. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
[TBL] [Abstract][Full Text] [Related]
12. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
Sarup J; Jin P; Turin L; Bai X; Beryt M; Brdlik C; Higaki JN; Jorgensen B; Lau FW; Lindley P; Liu J; Ni I; Rozzelle J; Kumari R; Watson SA; Zhang J; Shepard HM
Mol Cancer Ther; 2008 Oct; 7(10):3223-36. PubMed ID: 18852126
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
Spiridon CI; Guinn S; Vitetta ES
Clin Cancer Res; 2004 May; 10(10):3542-51. PubMed ID: 15161714
[TBL] [Abstract][Full Text] [Related]
16. Engineered IgG1-Fc--one fragment to bind them all.
Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
[TBL] [Abstract][Full Text] [Related]
17. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
19. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
20. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]